P r a ctica l Syn th esis a n d Ela bor a tion of
Meth yl 7-Ch lor oin d ole-4-ca r boxyla te
Phil B. Alper* and KhanhLinh T. Nguyen
The Genomics Institute of the Novartis Foundation,
10675 J ohn J ay Hopkins, San Diego, California 92121-1125
palper@gnf.org
Received September 10, 2002
F IGURE 1. Representative indole-containing substances.
Abstr a ct: A synthesis of a previously unknown indole
derivative is presented. The route reported herein allows for
the preparation of multihundred gram quantities of material
without any chromatographic purification. Conditions are
presented for the Pd-catalyzed elaboration of one of the
“diversity generating elements” of this important pharma-
cophore.
F IGURE 2. Designed indole scaffold and proposed starting
material.
The prominence of the indole nucleus in medicinally
important natural products and synthetic pharmaceuti-
cals can hardly be overstated.1 As a result, the chemistry
of the substituted indole has received an enormous
amount of attention.2 The revolution of combinatorial
chemistry of small molecules3 assured that the synthesis
of indole-containing lead compounds would be accelerated
in a manner similar to all other scaffolds.4
It was the tremendous variety of biological activities
associated with indoles that made them a scaffold of
choice for a multiple assay high throughput screening
effort such as the one at our institute. We wanted to
design an indole core that would allow for synthesis of a
diverse set of molecules, which could elicit the greatest
possible variety of biological responses possible from a
single starting point.
When thinking about the design of such a scaffold, it
was desirable to leave the pyrrole ring unsubstituted
since this ring has a rich chemistry associated with it.
To introduce appropriate handles for diversification
chemistry, we needed to choose which positions of the
benzene ring were to be modified.
Figure 1 shows three natural products that have
nonrelated biological activities. Lysergic acid diethyl
amide (1) is a hallucinogen and CNS activator5 in
addition to a plethora of physiological effects.6 Hippadine
(2) causes reversible inhibition of fertility in male rats
without antimitotic activity.7 (-)-7-Octylindolactam V (3)
is a protein kinase C modulator.8 The structural proper-
ties that these molecules share is their substitution in
positions 4 and 7 of the indole nucleus. It was therefore
decided to equip our scaffold with chemically orthogonal
substituents at positions 4 and 7.
Figure 2 shows the structure of the scaffold 4 chosen
for further study along with the proposed starting mate-
rial 5. With the inherent alkylative, electrophilic, and
nucleophilic properties of positions 1, 2, and 3 and the
diverse chemistries available to the substituents at
(4) (a) Hutchins, S. M.; Chapman, K. T. Tetrahedron Lett. 1996,
37(28), 4869. (b) Yun, W.; Mohan, R. Tetrahedron Lett. 1996, 37(40),
7189. (c) Hughes, I. Tetrahedron Lett. 1996, 37(42), 7595. (d) Cheng,
Y.; Chapman, K. T. Tetrahedron Lett. 1997, 38(9), 1497. (e) Fagnola,
M. C.; Visentin, I. C. G.; Cabri, W.; Zarini, F.; Mongelli, N.; Bedeschi,
A. Tetrahedron Lett. 1997, 38(13), 2307. (f) Zhang, H.-C.; Marianoff,
B. E. J . Org. Chem. 1997, 62, 1804. (g) Arumugam, V.; Routledge, A.;
Abell, C.; Balasubramanian, S. Tetrahedron Lett. 1997, 38(36), 6473.
(h) Collini, M. D.; Ellingboe, J . W. Tetrahedron Lett. 1997, 38(46), 7963.
(i) Fokas, D.; Ryan, W. J .; Casebier, D. S.; Coffen, D. L. Tetrahedron
Lett. 1998, 39, 2235. (j) Zhang, H.-C.; Brumfield, K. K.; J aroskova, L.;
Maryanoff, B. E. Tetrahedron Lett. 1998, 39, 4449. (k) Smith, A. L.;
Stevenson, G. I.; Swain, C. J .; Castro, J . L. Tetrahedron Lett. 1998,
39, 8317. (l) Wang, Y.; Huang, T.-N. Tetrahedron Lett. 1998, 39, 9605.
(m) Stephensen, H.; Zaragoza, F. Tetrahedron Lett. 1999, 40, 5799.
(n) Wang, H.; Ganesan, A. Org. Lett. 1999, 1(10), 1647. (o) Zhang, H.-
C.; Ye, H.; Moretto, A. F.; Brumfield, K. K.; Maryanoff, B. E. Org. Lett.
2000, 2(1), 89. (p) Kraxner, J .; Arlt, M. Gmeiner, P. Synlett 2000,(1),
125. (q) Tois, J .; Franzen, R.; Aitio, O.; Huikko, K.; Taskinen, J .
Tetrahedron Lett. 2000, 41, 2443. (r) Ketcha, D. M.; Wilson, L. J .;
Portlock, D. E. Tetrahedron Lett. 2000, 41, 6253. (s) Smith, A.;
Stevenson, G. I.; Lewis, S.; Patel, S.; Castro, J . L. Bioorg. Med. Chem.
Lett. 2000, 10, 2693. (t) Stevenson, G. I.; Smith, A. L.; Lewis, S.; Michie,
S. G.; Neduvelil, J . G.; Patel, Sm.; Marwood, R.; Patel, Sh.; Castro, J .
L. Bioorg. Med. Chem. Lett. 2000, 10, 2697. (u) Nettekoven, M.
Tetrahedron Lett. 2000, 41, 8251. (v) Meseguer, B.; Alonso-Diaz, D.;
Griebenow, N.; Herget, T.; Waldmann, H. Chem. Eur. J . 2001, 6(21),
3943. (w) Cooper, L. C.; Chicchi, G. G.; Dinell, K.; Elliott, J . M.;
Hollingsworth, G. J .; Kurtz, M. M.; Locker, K. L.; Morrison, D.; Shaw,
D. E.; Tsao, K.-L.; Watt, A. P.; Williams, A. R.; Swain, C. J . Bioorg.
Med. Chem. Lett. 2001, 11, 1233.
(1) (a) Gribble, G. W. In Comprehensive Heterocyclic Chemistry II;
Katritzky, A. R., Rees, C. W., Scriven, E. F. V., Eds.; Pergamon: New
York, 1996; Vol. 2, p 207. (b) Ban, Y.; Murakami, Y.; Iwasawa, Y.;
Tsuchia, M.; Takano, N. Med. Res. Rev. 1998, 8 (2), 231. (c) Saxton, J .
E. The Chemistry of Heterocyclic Compounds; Wiley: New York, 1983;
Vol. 25, Part IV.
(2) For some leading reviews, see: (a) Gribble, G. W. J . Chem. Soc.,
Perkin Trans. 1 2000, 1045. (b) Sundberg, R. J . In Comprehensive
Heterocyclic Chemistry II; Katritzky, A. R., Rees, C. W., Scriven, E. F.
V., Eds.; Pergamon: New York, 1996; Vol. 2, p 119. (c) Hughes, D. L.
Org. Prep. Proc. Int. 1993, 607.
(5) (a) J enner, P.; Luscombe, G.; Marsden, C. D. Br. J . Pharmocol.
1983, 80, Suppl. 667P. (b) Kaiser, C.; J ain, T. Med. Res. Rev. 1985, 5,
145.
(6) (a) Bowers, M. B., J r.; Salamonsson, L. A. Biochem. Pharmocol.
1982, 31, 4093. (b) Mornex, R.; Hugues, B. J . Pharmocol. 1983, 14
(Suppl. 3), 81.
(3) For some introductory reviews, see: (a) Gordon, E. M.; Barrett,
R. W.; Dower, W. J .; Fodor, S. P. A.; Gallop, M. A. J . Med. Chem. 1994,
37(10), 1385. (b) Thompson, L. A.; Ellman, J . A. Chem. Rev. 1996, 96,
555. (c) Balkenhohl, F.; von dem Bussche-Hunnefeld, C.; Lansky, A.;
Zechel, C. Angew. Chem., Int. Ed. Engl. 1996, 35, 2288.
(7) Chattopadhyay, S.; Chattopadhyay, U.; Mathur, P. P.; Saini, K.
S.; Ghosal, S. Planta Med. 1983, 49, 252.
(8) Kazanietz, M. G.; Areces, L. B.; Bahador, A.; Mischak, H.;
Goodnight, J .; Mushinski, J . F.; Blumberg, P. M. Mol. Pharmacol. 1993,
44, 298.
10.1021/jo026434p CCC: $25.00 © 2003 American Chemical Society
Published on Web 02/08/2003
J . Org. Chem. 2003, 68, 2051-2053
2051